^
    Back
    Association details:
    Biomarker:ER positive + PIK3CA H1047R
    Cancer:Breast Cancer
    Drug:camizestrant (AZD9833) (Selective estrogen receptor degrader) +
    OKI-219 (PI3Kα H1047R mutation inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    SABCS 2023
    Title:

    OKI-219, a PI3KαH1047R-mutant-selective inhibitor demonstrates efficacy as a single agent and drives combination responses with standard of care therapies in pre-clinical PI3KαH1047R mutant breast cancer models.

    Published date:
    12/02/2023
    Excerpt:
    Moreover, OKI-219 dosed in combination with the selective estrogen receptor degraders (SERDs) fulvestrant, elacestrant or camizestrant showed significant combination benefit leading to tumor regressions of up to 100% in the ER+ H1047R mutant breast cancer model xxT47D, at doses where no regressions were observed with single agent treatment.